These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 15804353)

  • 61. The antimycobacterial activity of a peptide preparation derived from calf thymus.
    DUBOS RJ; HIRSCH JG
    J Exp Med; 1954 Jan; 99(1):55-63. PubMed ID: 13118063
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Rv0579 Is Involved in the Resistance to the TP053 Antitubercular Prodrug.
    Mori G; Orena BS; Chiarelli LR; Degiacomi G; Riabova O; Sammartino JC; Makarov V; Riccardi G; Pasca MR
    Front Microbiol; 2020; 11():292. PubMed ID: 32158439
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [The bactericidal effects of an amphoteric surfactant with ethanol against Mycobacterium tuberculosis].
    Sato A; Ohishi H; Sakashita T
    Kansenshogaku Zasshi; 1995 Jan; 69(1):91-7. PubMed ID: 7751742
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Mycobacterium aurum is Unable to Survive Mycobacterium tuberculosis Latency Associated Stress Conditions: Implications as Non-suitable Model Organism.
    Sood S; Yadav A; Shrivastava R
    Indian J Microbiol; 2016 Jun; 56(2):198-204. PubMed ID: 27570312
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Dual-Mechanism Confers Self-Resistance to the Antituberculosis Antibiotic Capreomycin.
    Pan YC; Wang YL; Toh SI; Hsu NS; Lin KH; Xu Z; Huang SC; Wu TK; Li TL; Chang CY
    ACS Chem Biol; 2022 Jan; 17(1):138-146. PubMed ID: 34994196
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Drug Susceptibility Screening Using In Vitro Models of Hypoxic Non-Replicating Persistent Mycobacteria.
    Gibson SER; Harrison J; Cox JAG
    Methods Mol Biol; 2021; 2314():247-260. PubMed ID: 34235656
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Models of latent tuberculosis: their salient features, limitations, and development.
    Patel K; Jhamb SS; Singh PP
    J Lab Physicians; 2011 Jul; 3(2):75-9. PubMed ID: 22219558
    [TBL] [Abstract][Full Text] [Related]  

  • 68. The impurities of capreomycin make a difference in the safety and pharmacokinetic profiles.
    Lee SH; Shin J; Choi JM; Lee EY; Kim DH; Suh JW; Chang JH
    Int J Antimicrob Agents; 2003 Jul; 22(1):81-3. PubMed ID: 12842334
    [No Abstract]   [Full Text] [Related]  

  • 69. Selective production of capreomycins through mutation and medium development.
    Brown MS; Doro AE; McArthur HA; Morse BK; Murphy TK; Wax RG
    J Antibiot (Tokyo); 1997 Aug; 50(8):696-7. PubMed ID: 9315085
    [No Abstract]   [Full Text] [Related]  

  • 70. The chemical structure of capreomycin.
    Shiba T; Nomoto S; Wakamiya T
    Experientia; 1976 Sep; 32(9):1109-11. PubMed ID: 61134
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Newly Discovered Mechanisms of Antibiotic Self-Resistance with Multiple Enzymes Acting at Different Locations and Stages.
    Chen X; Pan HX; Tang GL
    Antibiotics (Basel); 2022 Dec; 12(1):. PubMed ID: 36671236
    [TBL] [Abstract][Full Text] [Related]  

  • 72. The pathogenic mechanism of Mycobacterium tuberculosis: implication for new drug development.
    Yan W; Zheng Y; Dou C; Zhang G; Arnaout T; Cheng W
    Mol Biomed; 2022 Dec; 3(1):48. PubMed ID: 36547804
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Application of Mycobacterium smegmatis as a surrogate to evaluate drug leads against Mycobacterium tuberculosis.
    Lelovic N; Mitachi K; Yang J; Lemieux MR; Ji Y; Kurosu M
    J Antibiot (Tokyo); 2020 Nov; 73(11):780-789. PubMed ID: 32472054
    [TBL] [Abstract][Full Text] [Related]  

  • 74. How do cyclic antibiotics with activity against Gram-negative bacteria permeate membranes? A machine learning informed experimental study.
    Lee MW; de Anda J; Kroll C; Bieniossek C; Bradley K; Amrein KE; Wong GCL
    Biochim Biophys Acta Biomembr; 2020 Aug; 1862(8):183302. PubMed ID: 32311341
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Modelling a Silent Epidemic: A Review of the In Vitro Models of Latent Tuberculosis.
    Gibson SER; Harrison J; Cox JAG
    Pathogens; 2018 Nov; 7(4):. PubMed ID: 30445695
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Optimization and Evaluation of 5-Styryl-Oxathiazol-2-one Mycobacterium tuberculosis Proteasome Inhibitors as Potential Antitubercular Agents.
    Russo F; Gising J; Åkerbladh L; Roos AK; Naworyta A; Mowbray SL; Sokolowski A; Henderson I; Alling T; Bailey MA; Files M; Parish T; Karlén A; Larhed M
    ChemistryOpen; 2015 Jun; 4(3):342-62. PubMed ID: 26246997
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Phase I, single-dose, dose-escalating study of inhaled dry powder capreomycin: a new approach to therapy of drug-resistant tuberculosis.
    Dharmadhikari AS; Kabadi M; Gerety B; Hickey AJ; Fourie PB; Nardell E
    Antimicrob Agents Chemother; 2013 Jun; 57(6):2613-9. PubMed ID: 23529740
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Old drugs, new purpose: retooling existing drugs for optimized treatment of resistant tuberculosis.
    Dooley KE; Mitnick CD; Ann DeGroote M; Obuku E; Belitsky V; Hamilton CD; Makhene M; Shah S; Brust JC; Durakovic N; Nuermberger E;
    Clin Infect Dis; 2012 Aug; 55(4):572-81. PubMed ID: 22615332
    [TBL] [Abstract][Full Text] [Related]  

  • 79.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.